AR013520A1 - Metodo de preparacion de un dispositivo de administracion transdermal, dispositivo de administracion transdermal y utilizacion de un esteroide comoaditivo en un dispositivo de administracion transdermal - Google Patents

Metodo de preparacion de un dispositivo de administracion transdermal, dispositivo de administracion transdermal y utilizacion de un esteroide comoaditivo en un dispositivo de administracion transdermal

Info

Publication number
AR013520A1
AR013520A1 ARP980104789A ARP980104789A AR013520A1 AR 013520 A1 AR013520 A1 AR 013520A1 AR P980104789 A ARP980104789 A AR P980104789A AR P980104789 A ARP980104789 A AR P980104789A AR 013520 A1 AR013520 A1 AR 013520A1
Authority
AR
Argentina
Prior art keywords
transdermal administration
administration device
hormone
steroid
combination
Prior art date
Application number
ARP980104789A
Other languages
English (en)
Original Assignee
Ethical Pharmaceuticals South America S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethical Pharmaceuticals South America S A filed Critical Ethical Pharmaceuticals South America S A
Publication of AR013520A1 publication Critical patent/AR013520A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Método de preparacion de un dispositivo de administracion transdernal, dispositivo de administracion transdernal y un esteroide como aditivo en undispositivo de administracion transdernal. El método de preparacion del dispositivo deadmi nistracion transdernal incluye los pasos de: (a) preparacionde la mezcla de, al menos, una primera hormona o combinacion de hormonas en una cantidad suficiente para provocar un efecto terapéutico durante el uso deldispositivo y los materialesque con stituyen la matriz en los cuales dicha primera hormona o combinacion de hormonas es distribuida, (b) disposicion dedicha mezcla en o sobre un soporte para formar una matriz que contenga dicha primera hormona o combinacion dehormonas, (c) inc lusion en la mezcla de unacantidad medida de un esteroide, teniendo dicha cantidad medida un efecto de inhibicion de la cristalizacion de la primera hormona o combinacion de hormonasal almacenar el dispositivo completo, peroestando dicho esteroid e en una cantidad insuficiente para provocar un efecto fisiologico o terapéuticosignificativo cuando el dispositivo es usado. El dispositivo de administracion transdermal está constituido por un cuerpo de material y unsoporte para éste,conten iendo el cuerpo del material una primera hormona o combinacion de hormonas en una cantidad suficiente como para provocar un efecto terapéuticocuando el dispositivo es usado y, como inhibidor de la cristalizacion dedicha primera hormona o co mbinacion de hormonas, un esteroide, el cual está presenteen una cantidad mayor que la que existe normalmente como impureza, pero suficiente como para provocar algun efecto farmacologico o terapéuticosignificativocuando el dispositivo es usa do. El uso de un esteroide como aditivo en el proceso de manufactura de un dispositivo transdernal actuando
ARP980104789A 1997-09-25 1998-09-25 Metodo de preparacion de un dispositivo de administracion transdermal, dispositivo de administracion transdermal y utilizacion de un esteroide comoaditivo en un dispositivo de administracion transdermal AR013520A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9720470.5A GB9720470D0 (en) 1997-09-25 1997-09-25 Inhibition of crystallization in transdermal devices

Publications (1)

Publication Number Publication Date
AR013520A1 true AR013520A1 (es) 2000-12-27

Family

ID=10819670

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104789A AR013520A1 (es) 1997-09-25 1998-09-25 Metodo de preparacion de un dispositivo de administracion transdermal, dispositivo de administracion transdermal y utilizacion de un esteroide comoaditivo en un dispositivo de administracion transdermal

Country Status (8)

Country Link
US (1) US6465005B1 (es)
EP (1) EP1023055B1 (es)
AR (1) AR013520A1 (es)
BR (1) BR9812523A (es)
DE (1) DE69803592T2 (es)
ES (1) ES2172195T3 (es)
GB (1) GB9720470D0 (es)
WO (1) WO1999015156A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5325000A (en) 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
AU2001282064B2 (en) * 2000-08-03 2007-02-01 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20020106402A1 (en) * 2000-12-05 2002-08-08 Hartwig Rod Lawson Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
DK1406633T3 (da) * 2001-06-18 2011-10-31 Noven Pharma Forbedret lægemiddeltilførsel i transdermale systemer
US20040037873A1 (en) * 2002-05-30 2004-02-26 Watson Pharmaceuticals, Inc. Norethindrone sustained release formulations and methods associated therewith
US20050058695A1 (en) * 2002-05-30 2005-03-17 Watson Pharmaccuticals, Inc. Norethindrone sustained release formulations and methods associated therewith
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
PT1670433E (pt) 2003-10-10 2012-02-08 Ferring Bv Fórmula farmacológica transdérmica para a minimização de resíduos na pele
TW200514582A (en) * 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
FR2895679B1 (fr) * 2005-12-29 2012-06-08 Pf Medicament Stabilisation de testosterone au sein de dispositifs transdermiques
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US20080226698A1 (en) 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
EP2349230A2 (en) 2008-10-06 2011-08-03 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
CA2854164C (en) * 2011-11-04 2021-04-13 Agile Therapeutics, Inc. Dermal delivery compositions and methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4832953A (en) 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US4906475A (en) 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
WO1989007951A1 (en) 1988-02-26 1989-09-08 Riker Laboratories, Incorporated Transdermal estradiol delivery system
US4814168A (en) 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
WO1990006120A1 (en) 1988-12-01 1990-06-14 Schering Corporation Compositions for transdermal delivery of estradiol
AR246186A1 (es) 1989-11-17 1994-07-29 Beta Pharm Co Procedimiento para fabricar un dispositivo para administrar estradiol por via transdermica.
GB9021674D0 (en) 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
DE4210711A1 (de) * 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
DE4429664C2 (de) 1994-08-20 1997-09-11 Lohmann Therapie Syst Lts Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same

Also Published As

Publication number Publication date
DE69803592T2 (de) 2002-09-19
EP1023055A1 (en) 2000-08-02
EP1023055B1 (en) 2002-01-23
US6465005B1 (en) 2002-10-15
ES2172195T3 (es) 2002-09-16
WO1999015156B1 (en) 1999-06-10
WO1999015156A1 (en) 1999-04-01
GB9720470D0 (en) 1997-11-26
BR9812523A (pt) 2000-07-25
DE69803592D1 (de) 2002-03-14

Similar Documents

Publication Publication Date Title
AR013520A1 (es) Metodo de preparacion de un dispositivo de administracion transdermal, dispositivo de administracion transdermal y utilizacion de un esteroide comoaditivo en un dispositivo de administracion transdermal
US5152997A (en) Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
KR100492676B1 (ko) 2종이상의활성물질을위한약물전달시스템
ES2553101T3 (es) Precursor de esteroides sexuales en combinación con un modulador selectivo del receptor de estrógenos para la prevención y tratamiento de atrofia vaginal en mujeres postmenopáusicas
AU741482B2 (en) Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
CN101940790B (zh) 一种新型促渗剂组合物及其在透皮给药系统中的应用
DK1089722T3 (da) Transdermalt plaster af matrixtypen til steroidhormoner
BRPI0713257A2 (pt) sistema terapêutico transdérmico contendo norelgestromina para a contracepção e reposição hormonal
KR900015761A (ko) 경피성 단일체 시스템
ES2893527T3 (es) Parche
PT95245B (pt) Sistema de matriz solida para a libertacao transdermica de farmacos
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
KR960705554A (ko) 산화질소 합성 효소 기질 및(또는) 공여체를 사용한 갱년기 질병의 치료 방법(Treatment of Climacteric Disorders with Nitric Oxide Synthase Substrates and/or Donors)
BG108634A (en) Injectable compositions for the controlled delivery of pharmacologically active compound
AR031563A1 (es) Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
CO5540373A2 (es) Composicion farmaceutica de liberacion sostenida
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
AU2003213842A1 (en) Sulfatase inhibiting continuous progestogen contraceptive regimens
ECSP066694A (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
AR046762A1 (es) Hormonas de administracion transdermica que no necesitan potenciadores de penetracion
Miyake et al. Progesterone facilitates the LRH releasing action of oestrogen
AU2003252139A1 (en) Extended transdermal contraceptive regimens
Ibarra de Palacios et al. Comparative study to evaluate skin irritation and adhesion of Estradot® and Climara® in healthy postmenopausal women
Coutinho et al. The response of the human Fallopian tube to ergonovine and methyl-ergonovine in vivo

Legal Events

Date Code Title Description
FB Suspension of granting procedure